Inclusion Criteria:
1. Age \>18 years on the day of signing the Informed Consent Form;
2. The subject is able to comprehend the procedures and methods of this clinical study, and voluntarily signs the informed consent form after providing full informed consent.
3. Gastric or gastroesophageal junction cancer (HER2-negative) confirmed by histology or cytology;
4. Diagnosed via laparoscope as initially resectable gastric cancer/gastroesophageal junction cancer, accompanied by positive cytology in abdominal cavity washing solution, and/or low-burden peritoneal metastasis (peritoneal cancer index PCI ≤ 10);
5. ECOG PS 0-2, expected survival ≥3 months;
6. Organ function meets the following criteria (within 10 days of first receiving the Investigational Product);
1. Hematology: Platelet count ≥100×10⁹/L, hemoglobin ≥8g/dL, ANC ≥1.5×10⁹/L, and no blood products, erythropoiesis-stimulating agents, or colony-stimulating factors therapy received within the past 7 days;
2. Renal function: Serum creatinine is within the normal upper limit range set by the institution;
3. Liver function: Total bilirubin ≤ 1.5×UNL; if total bilirubin \> 1.5×UNL, then direct bilirubin should be ≤ UNL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both ≤ 2.5×UNL, albumin \> 2.5 mg/dL;
4. Coagulation function: International normalized ratio (INR), prothrombin time (PT), activated partial thromboplastin time (APTT) ≤ 1.5×UNL; if the subject is undergoing anticoagulation therapy, it should be within the established therapeutic range;
7. For women of childbearing potential, the serum pregnancy test within 72 hours prior to the first administration of the investigational product must be negative. If the urine test result is positive or cannot be confirmed as negative, further serum pregnancy testing is required.
8. Women of childbearing age should agree to use two effective methods of birth control or undergo surgical sterilization, or choose to avoid any heterosexual intercourse throughout the study period and for 120 days after the last drug administration. (Women who have been postmenopausal for more than one year and have not undergone surgical sterilization are considered infertile.) Lactating women must cease breastfeeding.
9. Male subjects should agree to adopt effective contraceptive measures from the first administration until 120 days after the final administration.
Exclusion Criteria:
1. There is distant metastasis outside the peritoneum.
2. Peritoneal cancer index (PCI) \> 10;
3. Siewert type I squamous cell carcinoma of the gastroesophageal junction, primarily involving the esophagus;
4. Presence of active central nervous system metastasis or meningitis carcinomatosa;
5. There is an uncontrolled abdominal infection, intestinal obstruction, grade 3 abdominal effusion, or a risk of gastrointestinal fistula or perforation;
6. Diagnostic biopsy confirmed EB virus positive, microsatellite instability (MSI) positive, and human epidermal growth factor receptor 2 (HER2) positive.
7. Received systemic immunosuppressant therapy within 28 days prior to the study;
8. Known to have an allergy to any investigational product or any excipient of the investigational product;
9. Diagnosed with another malignancy within the past 5 years, and the tumor is currently in a progressive stage or requires treatment (excluding basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or cervical carcinoma in situ that has undergone potentially curative treatment);
10. There is active autoimmune disease, and systemic therapy (including the use of disease-modifying drugs, corticosteroids, or immunosuppressants) has been received in the past two years. Replacement therapy (e.g., thyroxine replacement for hypothyroidism, insulin therapy for diabetes mellitus, or physiological glucocorticoid supplementation for adrenal or pituitary insufficiency) is not considered systemic therapy.
11. Previously suffered from (non-infectious) pneumonia requiring glucocorticoid therapy, or currently suffering from pneumonia;
12. There is an active infection requiring systemic therapy.
13. The presence of any history of disease, therapy, or laboratory abnormalities that may interfere with the test results, affect the subject's full participation, or be deemed unsuitable for the subject's participation in the study by the Sub investigator;
14. Past or current mental disease or drug abuse, deemed by the Sub investigator as unable to comply with trial requirements;
15. Already pregnant or in the lactation period, or plans to become pregnant or cause a woman to become pregnant during the trial period (from the start of pre-screening or screening visit to 120 days after the final administration);
16. Known infection with Human Immunodeficiency Virus (HIV1/2 antibody positive);
17. Presence of active hepatitis B (Hepatitis B Surface Antigen \[HBsAg\] positive and HBV DNA above 1000 copies/ml or 200 IU/ml) or hepatitis C (HCV antibody \[HCVAb\] positive and HCV RNA above the lower limit of detection at the study center);
18. Received any live vaccine within 30 days prior to the first use of the investigational medicinal product.
